Medacta Group SA

SWX:MOVE 주식 보고서

시가총액: CHF 2.7b

Medacta Group 관리

관리 기준 확인 4/4

Medacta Group CEO는 Francesco Siccardi, Nov2018 에 임명되었습니다 의 임기는 6.58 년입니다. 총 연간 보상은 € 2.00M, 19.6% 로 구성됩니다. 19.6% 급여 및 80.4% 보너스(회사 주식 및 옵션 포함). 는 CHF 535.37M 가치에 해당하는 회사 주식의 19.91% 직접 소유합니다. 535.37M. 경영진과 이사회의 평균 재임 기간은 각각 11.9 년과 6.4 년입니다.

주요 정보

Francesco Siccardi

최고 경영자

€2.0m

총 보상

CEO 급여 비율19.61%
CEO 임기6.6yrs
CEO 소유권19.9%
경영진 평균 재임 기간11.9yrs
이사회 평균 재임 기간6.4yrs

최근 관리 업데이트

Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Recent updates

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

May 24
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher

May 10
Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher

Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Apr 24
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing

Apr 10
Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing

Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 28
Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year

Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump

Feb 13
Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump
author-image

New Products Like GMK SpheriKA And NextAR Will Strengthen Future Prospects In The Spine Segment

Medacta's innovation in product launches and medical education expansion drives revenue growth, with a strong focus on the Spine segment and ASCs.

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Jan 06
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

The Price Is Right For Medacta Group SA (VTX:MOVE)

Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16
Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20
The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02
Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28
Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31
These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07
Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05
Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26
Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20
Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05
We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02
What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02
Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12
The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

CEO 보상 분석

Francesco Siccardi 의 보수는 Medacta Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Dec 31 2024€2m€392k

€73m

Sep 30 2024n/an/a

€65m

Jun 30 2024n/an/a

€56m

Mar 31 2024n/an/a

€52m

Dec 31 2023€2m€396k

€47m

Sep 30 2023n/an/a

€49m

Jun 30 2023n/an/a

€50m

Mar 31 2023n/an/a

€48m

Dec 31 2022€2m€372k

€46m

Sep 30 2022n/an/a

€47m

Jun 30 2022n/an/a

€47m

Mar 31 2022n/an/a

€49m

Dec 31 2021€2m€354k

€52m

Sep 30 2021n/an/a

€54m

Jun 30 2021n/an/a

€57m

Mar 31 2021n/an/a

€47m

Dec 31 2020€1m€339k

€37m

Sep 30 2020n/an/a

€24m

Jun 30 2020n/an/a

€10m

Mar 31 2020n/an/a

€11m

Dec 31 2019€843k€247k

€12m

보상 대 시장: Francesco 의 총 보상 ($USD 2.27M )은 Swiss 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.75M ).

보상과 수익: Francesco 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Francesco Siccardi (48 yo)

6.6yrs
테뉴어
€1,997,619
보상

Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...

리더십 팀

이름위치테뉴어보상소유권
Alberto Siccardi
Founder & Non Executive Chairman7.4yrs€346.42k10.2%
CHF 274.3m
Francesco Siccardi
Chief Executive Officer6.6yrs€2.00m19.91%
CHF 535.4m
Corrado Farsetta
Chief Financial Officer14.4yrs데이터 없음데이터 없음
Gianluca Olgiati
Senior Director of Global Marketingno data데이터 없음데이터 없음
Asif Hussain
Chief People Officerno data데이터 없음데이터 없음
Alessandro Siccardi
Chief Supply Chain Officer9.4yrs데이터 없음19.81%
CHF 532.7m
Filippo Cappelli
Head of ITno data데이터 없음데이터 없음
Giovanni Galli
Chief Commercial Officerno data데이터 없음데이터 없음
Massimiliano Bernardoni
Chief Innovation Officerno data데이터 없음데이터 없음
Donato Cortesi
Secretary of the Boardno data데이터 없음데이터 없음
Antonio Di Brino
Group Vice President of Finance & Taxno data데이터 없음데이터 없음
11.9yrs
평균 재임 기간
52yo
평균 연령

경험이 풍부한 관리: MOVE 의 관리팀은 노련하고 경험 (평균 재직 기간 11.9 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Alberto Siccardi
Founder & Non Executive Chairman7.4yrs€346.42k10.2%
CHF 274.3m
Victor Balli
Lead Independent Director6.4yrs€228.29k0.013%
CHF 337.5k
Riccardo Braglia
Independent Director4.5yrs€127.15k0.16%
CHF 4.4m
Philippe Weber
Independent Director6.3yrs€150.26k데이터 없음
Maria Siccardi Tonolli
Non-executive Director7.4yrs€135.95k19.81%
CHF 532.7m
6.4yrs
평균 재임 기간
65yo
평균 연령

경험이 풍부한 이사회: MOVE 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터마지막 업데이트(UTC 시간)
기업 분석2025/06/02 06:46
장 마감 주가2025/05/30 00:00
수익2024/12/31
연간 수익2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
회사 재무10년
  • 손익 계산서
  • 현금 흐름표
  • 대차 대조표
애널리스트 컨센서스 추정치+3년
  • 재무 예측
  • 애널리스트 목표가
시장 가격30년
  • 주식 가격
  • 배당금, 분할 및 액션
소유권10년
  • 최대 주주
  • 내부자 거래
관리10년
  • 리더십 팀
  • 이사회
주요 개발 사항10년
  • 회사 공지 사항

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Medacta Group SA 13 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가교육기관
Samuel EnglandBerenberg
Maria Vara FernándezBryan Garnier & Co
Christoph GretlerCredit Suisse